Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Group 1 - Corbus Pharmaceuticals Holdings, Inc. will participate in the Piper Sandler 3rd Annual Virtual Obesity Symposium on June 26, 2025, with CEO Yuval Cohen, Ph.D. engaging in a fireside chat [1][2] - The symposium will feature presentations from key opinion leaders and discussions with companies focused on obesity therapeutics [1] - Corbus is a clinical-stage company concentrating on oncology and obesity, with a commitment to innovative scientific approaches targeting well-understood biological pathways [2] Group 2 - Corbus' pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells, CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation, and CRB-913, a CB1 receptor inverse agonist for obesity treatment [2] - The company is headquartered in Norwood, Massachusetts, and provides additional information through its website and social media platforms [2]